Moderna, a biotech developing therapies based on its modified mRNA platform, filed on Friday with the SEC to raise up to $500 million in an initial public offering.
The Cambridge, MA-based company was founded in 2010 as Moderna Therapeutics. It booked $192 million in collaboration and grant revenue for the 12 months ended September 30, 2018. It plans to list on the Nasdaq under the symbol MRNA. Moderna filed confidentially on August 30, 2018. Morgan Stanley, Goldman Sachs, J.P. Morgan, BofA Merrill Lynch, Barclays, Piper Jaffray and Bryan, Garnier & Co are the joint bookrunners on the deal. No pricing terms were disclosed.
